Company Overview
Snapshot
Founded in January 1962, Mego Afek AC operates with 51–200 employees. The company has raised $22.44 million across three funding rounds from one investor.
Business overview
Mego Afek AC specializes in the development and manufacturing of medical and aesthetic compression therapy systems. Leveraging its expertise in compression technology, the company produces the Lympha Press line of medical devices for treating lymphedema, venous insufficiency, and peripheral arterial disease, as well as systems for deep vein thrombosis prevention. Additionally, Mego Afek offers aesthetic solutions and therapeutic techniques for muscular recovery and rehabilitation for sports enthusiasts. The company serves home care, clinics, and hospitals within the Health Tech & Life Sciences sector, with products like Phlebo Press and Ballancer.
Strategic signal
In June 2021, Mego Afek AC became the first Israeli company to sell its products in Morocco. This strategic market entry signals the company's intent to expand its global footprint and tap into new regional healthcare markets, demonstrating a proactive approach to international growth and market diversification for its compression therapy systems.
Log in to access full profile ›Company Intelligence Q&A
- What is Mego Afek AC's primary focus?
- Mego Afek AC specializes in developing and manufacturing medical and aesthetic compression therapy systems for home care, clinics, and hospitals.
- When was Mego Afek AC founded?
- Mego Afek AC was founded in January 1962.
- What was a significant market expansion for Mego Afek AC?
- In June 2021, Mego Afek AC became the first Israeli company to sell its products in Morocco, marking a significant step in its international market expansion.
- What is the Lympha Press line of products?
- The Lympha Press line consists of medical devices developed by Mego Afek AC for the treatment of lymphedema, venous insufficiency, and for preventing deep vein thrombosis.